Caution - Investigational Device Limited by United States Law to Investigational Use
Background
Nearly 190,000 men in the US are diagnosed with prostate cancer annually. With early identification and treatment, prostate cancer has a cure rate of over 90%.
Several HIFU manufacturers provide systems using ultrasound guidance. The ExAblate system, based on MRI guidance, uses accurate real-time temperature parameters to achieve the planned outcome.
Potential value of MRgFUS for prostate cancer:
• Treatment for early stage cancer
• Single session
• Low rate of complications
• No radiation
For more information please contact us.
